RxDoctor Payments Data

Jillian Fickenscher, MD

Family Medicine · Omaha, NENPI 1376988972

Payments from drug & device makers

$2,238in general payments, 2019–2025

Across 136 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$987
  • Novo Nordisk$228
  • Astellas Pharma US Inc$138
  • Johnson & Johnson$117
  • Amgen$88
  • Lilly USA, LLC$70
  • plus $610 from 22 others

What the payments were for

  • Food & beverage$2,238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,238 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$51,725
Medicare patients
140
Services billed
1,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$37,726
RybelsusSemaglutide30$36,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$27,980
EliquisApixaban29$27,669
XareltoRivaroxaban40$27,561
FarxigaDapagliflozin Propanediol34$22,019
TrulicityDulaglutide17$18,937
MounjaroTirzepatide17$18,729
JanuviaSitagliptin Phosphate20$15,114
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$12,527
BelsomraSuvorexant16$11,109
AbrysvoRsv Vacc, Pref A And Pref B/Pf27$8,711
Breo ElliptaFluticasone/Vilanterol13$8,432
InvokanaCanagliflozin12$6,737
Lacosamide27$4,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$228$74,45662 claims
Lilly USA, LLCTrulicity, Mounjaro$70$37,66634 claims
PfizerEliquis, Abrysvo$53$36,38056 claims
Johnson & JohnsonXarelto, Invokana$117$34,29852 claims
MerckJanuvia, Belsomra$34$26,22336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →